Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis (Q39793093)

14 September 2017

title

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis (English)

1 reference

14 September 2017

0 references

0 references

K Vandenbroucke

1

1 reference

14 September 2017

H de Haard

2

1 reference

14 September 2017

E Beirnaert

3

1 reference

14 September 2017

T Dreier

4

1 reference

14 September 2017

M Lauwereys

5

1 reference

14 September 2017

L Huyck

6

1 reference

14 September 2017

J Van Huysse

7

1 reference

14 September 2017

P Demetter

8

1 reference

14 September 2017

L Steidler

9

1 reference

14 September 2017

E Remaut

10

1 reference

14 September 2017

C Cuvelier

11

1 reference

14 September 2017

P Rottiers

12

1 reference

14 September 2017

publication date

30 September 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

3

1 reference

14 September 2017

issue

1

1 reference

14 September 2017

page(s)

49-56

1 reference

The immunological and genetic basis of inflammatory bowel disease

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Tumor necrosis factor: biology and therapeutic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

The pathophysiology of tumor necrosis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Optimizing anti-TNF treatment in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Potent enzyme inhibitors derived from dromedary heavy-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Selection and identification of single domain antibody fragments from camel heavy-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Secretion of biologically active murine interleukin-10 by Lactococcus lactis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Measurement of Cutaneous Inflammation: Estimation of Neutrophil Content with an Enzyme Marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Albumin binding as a general strategy for improving the pharmacokinetics of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Laboratory markers in IBD: useful, magic, or unnecessary toys?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Generation and Biological Characterization of Membrane-bound, Uncleavable Murine Tumor Necrosis Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Interleukin-10-deficient mice develop chronic enterocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

Infliximab-induced systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

7 January 2021

[Suspected cases of severe side effects after infliximab (Remicade) in Germany]

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

7 January 2021

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

7 January 2021

Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

7 January 2021

Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

7 January 2021

Murine monoclonal anti-tNF antibody administration has a beneficial effect on inflammatory bowel disease that develops in IL-10 knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

7 January 2021

Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

7 January 2021

A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

7 January 2021

Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice

1 reference

https://api.crossref.org/works/10.1038%2FMI.2009.116

7 January 2021

Identifiers

DOI

10.1038/MI.2009.116

1 reference

14 September 2017

1 reference